The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.

Innovator companies are increasingly engaging with outsourcing partners in efforts to improve cost and time efficiencies across the complete drug development lifecycle.

Luke Miels, the company’s current Chief Commercial Officer, has been appointed as the new CEO, signaling the company’s next phase after Dame Emma Walmsley’s era of strategic growth and innovation.

While the levies seem steep the impact on industry may be less severe than expected as many companies have a presence or are planning works for manufacturing facilities within the U.S., making them exempt from the tariffs.

Through the purchase the contract packaging organization will add 160,000 sq. ft. of manufacturing and warehouse facilities in Florida and will expand its capabilities and market segments.

Using its fully-connected continuous manufacturing technology, the CDMO has developed and scaled up pertuzumab to commercial launch readiness for the Indian market.

During CPHI Frankfurt, Sanner Group will unveil expanded CDMO capabilities and innovations in moisture management, with a joint presentation with Pfizer experts on next-generation drug delivery design.

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

Winners for each of the 14 categories will be chosen from the selected finalists and revealed during the CPHI Celebration event at CPHI Frankfurt on October 28, 2025.  

At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.

A deal worth up to USD 5.7 billion has been unveiled that is aimed at the development of molecular glue degraders for immune-mediated diseases utilizing Monte Rosa’s AI-driven QuEEN platform.

In light of the evolving therapeutic landscape, increasing use of advanced technologies, and political shifts, regulatory updates are inevitable, meaning that bio/pharma companies will need to adjust quickly to new requirements.

Several big players within the bio/pharma industry are pulling back their investments from the United Kingdom amid fears over the security of the country’s life sciences environment.

In this guest blog post, Will Downie and Elliott Berger delve into the key factors that are negatively impacting CDMO revenue performance and highlight the foundational elements that should be adopted to ensure success.

The companies have joined forces to launch an advanced lipid nanoparticle platform for RNA medicine delivery to advance the next generation of gene and vaccine therapies.

The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.